Cargando…
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected marker...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579100/ https://www.ncbi.nlm.nih.gov/pubmed/34777329 http://dx.doi.org/10.3389/fimmu.2021.672255 |
_version_ | 1784596372329070592 |
---|---|
author | Sánchez-Maldonado, Jose Manuel Cáliz, Rafael López-Nevot, Miguel Ángel Cabrera-Serrano, Antonio José Moñiz-Díez, Ana Canhão, Helena Ter Horst, Rob Quartuccio, Luca Sorensen, Signe B. Glintborg, Bente Hetland, Merete L. Filipescu, Ileana Pérez-Pampin, Eva Conesa-Zamora, Pablo Swierkot, Jerzy den Broeder, Alfons A. De Vita, Salvatore Petersen, Eva Rabing Brix Li, Yang Ferrer, Miguel A. Escudero, Alejandro Netea, Mihai G. Coenen, Marieke J. H. Andersen, Vibeke Fonseca, João E. Jurado, Manuel Bogunia-Kubik, Katarzyna Collantes, Eduardo Sainz, Juan |
author_facet | Sánchez-Maldonado, Jose Manuel Cáliz, Rafael López-Nevot, Miguel Ángel Cabrera-Serrano, Antonio José Moñiz-Díez, Ana Canhão, Helena Ter Horst, Rob Quartuccio, Luca Sorensen, Signe B. Glintborg, Bente Hetland, Merete L. Filipescu, Ileana Pérez-Pampin, Eva Conesa-Zamora, Pablo Swierkot, Jerzy den Broeder, Alfons A. De Vita, Salvatore Petersen, Eva Rabing Brix Li, Yang Ferrer, Miguel A. Escudero, Alejandro Netea, Mihai G. Coenen, Marieke J. H. Andersen, Vibeke Fonseca, João E. Jurado, Manuel Bogunia-Kubik, Katarzyna Collantes, Eduardo Sainz, Juan |
author_sort | Sánchez-Maldonado, Jose Manuel |
collection | PubMed |
description | We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected markers and evaluated their association with response to TNFi after 6 months of treatment according to the change in disease activity score 28 (ΔDAS28). Next, we confirmed the most interesting results through meta-analysis of our data with those from the DREAM cohort that included 706 RA patients treated with TNFi. The meta-analysis of the discovery cohort and DREAM registry including 2067 RA patients revealed an overall association of the LINC02549 (rs7767069) SNP with a lower improvement in DAS28 that remained significant after correction for multiple testing (per-allele OR(Meta)=0.83, P (Meta)=0.000077; P (Het)=0.61). In addition, we found that each copy of the LRRC55 (rs717117G) allele was significantly associated with lower improvement in DAS28 in rheumatoid factor (RF)-positive patients (per-allele OR(Meta)=0.67, P=0.00058; P (Het)=0.06) whereas an opposite but not significant effect was detected in RF-negative subjects (per-allele OR(Meta)=1.38, P=0.10; P (Het)=0.45; P (Interaction)=0.00028). Interestingly, although the identified associations did not survive multiple testing correction, the meta-analysis also showed overall and RF-specific associations for the MAFB (rs6071980) and CNTN5 (rs1813443) SNPs with decreased changes in DAS28 (per-allele OR(Meta_rs6071980) = 0.85, P=0.0059; P (Het)=0.63 and OR(Meta_rs1813443_RF+)=0.81, P=0.0059; P (Het)=0.69 and OR(Meta_rs1813443_RF-)=1.00, P=0.99; P (Het)=0.12; P (Interaction)=0.032). Mechanistically, we found that subjects carrying the LINC02549 (rs7767069T) allele had significantly increased numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the LINC02549 (rs7767069T/T) genotype showed significantly increased levels of soluble scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers of the LRRC55 (rs717117G) allele showed decreased production of IL6 after stimulation of PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549 and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak effect of the MAFB and CNTN5 loci that need to be further investigated. |
format | Online Article Text |
id | pubmed-8579100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85791002021-11-11 Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts Sánchez-Maldonado, Jose Manuel Cáliz, Rafael López-Nevot, Miguel Ángel Cabrera-Serrano, Antonio José Moñiz-Díez, Ana Canhão, Helena Ter Horst, Rob Quartuccio, Luca Sorensen, Signe B. Glintborg, Bente Hetland, Merete L. Filipescu, Ileana Pérez-Pampin, Eva Conesa-Zamora, Pablo Swierkot, Jerzy den Broeder, Alfons A. De Vita, Salvatore Petersen, Eva Rabing Brix Li, Yang Ferrer, Miguel A. Escudero, Alejandro Netea, Mihai G. Coenen, Marieke J. H. Andersen, Vibeke Fonseca, João E. Jurado, Manuel Bogunia-Kubik, Katarzyna Collantes, Eduardo Sainz, Juan Front Immunol Immunology We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected markers and evaluated their association with response to TNFi after 6 months of treatment according to the change in disease activity score 28 (ΔDAS28). Next, we confirmed the most interesting results through meta-analysis of our data with those from the DREAM cohort that included 706 RA patients treated with TNFi. The meta-analysis of the discovery cohort and DREAM registry including 2067 RA patients revealed an overall association of the LINC02549 (rs7767069) SNP with a lower improvement in DAS28 that remained significant after correction for multiple testing (per-allele OR(Meta)=0.83, P (Meta)=0.000077; P (Het)=0.61). In addition, we found that each copy of the LRRC55 (rs717117G) allele was significantly associated with lower improvement in DAS28 in rheumatoid factor (RF)-positive patients (per-allele OR(Meta)=0.67, P=0.00058; P (Het)=0.06) whereas an opposite but not significant effect was detected in RF-negative subjects (per-allele OR(Meta)=1.38, P=0.10; P (Het)=0.45; P (Interaction)=0.00028). Interestingly, although the identified associations did not survive multiple testing correction, the meta-analysis also showed overall and RF-specific associations for the MAFB (rs6071980) and CNTN5 (rs1813443) SNPs with decreased changes in DAS28 (per-allele OR(Meta_rs6071980) = 0.85, P=0.0059; P (Het)=0.63 and OR(Meta_rs1813443_RF+)=0.81, P=0.0059; P (Het)=0.69 and OR(Meta_rs1813443_RF-)=1.00, P=0.99; P (Het)=0.12; P (Interaction)=0.032). Mechanistically, we found that subjects carrying the LINC02549 (rs7767069T) allele had significantly increased numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the LINC02549 (rs7767069T/T) genotype showed significantly increased levels of soluble scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers of the LRRC55 (rs717117G) allele showed decreased production of IL6 after stimulation of PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549 and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak effect of the MAFB and CNTN5 loci that need to be further investigated. Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8579100/ /pubmed/34777329 http://dx.doi.org/10.3389/fimmu.2021.672255 Text en Copyright © 2021 Sánchez-Maldonado, Cáliz, López-Nevot, Cabrera-Serrano, Moñiz-Díez, Canhão, Ter Horst, Quartuccio, Sorensen, Glintborg, Hetland, Filipescu, Pérez-Pampin, Conesa-Zamora, Swierkot, den Broeder, De Vita, Petersen, Li, Ferrer, Escudero, Netea, Coenen, Andersen, Fonseca, Jurado, Bogunia-Kubik, Collantes and Sainz https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sánchez-Maldonado, Jose Manuel Cáliz, Rafael López-Nevot, Miguel Ángel Cabrera-Serrano, Antonio José Moñiz-Díez, Ana Canhão, Helena Ter Horst, Rob Quartuccio, Luca Sorensen, Signe B. Glintborg, Bente Hetland, Merete L. Filipescu, Ileana Pérez-Pampin, Eva Conesa-Zamora, Pablo Swierkot, Jerzy den Broeder, Alfons A. De Vita, Salvatore Petersen, Eva Rabing Brix Li, Yang Ferrer, Miguel A. Escudero, Alejandro Netea, Mihai G. Coenen, Marieke J. H. Andersen, Vibeke Fonseca, João E. Jurado, Manuel Bogunia-Kubik, Katarzyna Collantes, Eduardo Sainz, Juan Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts |
title | Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts |
title_full | Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts |
title_fullStr | Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts |
title_full_unstemmed | Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts |
title_short | Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts |
title_sort | validation of gwas-identified variants for anti-tnf drug response in rheumatoid arthritis: a meta-analysis of two large cohorts |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579100/ https://www.ncbi.nlm.nih.gov/pubmed/34777329 http://dx.doi.org/10.3389/fimmu.2021.672255 |
work_keys_str_mv | AT sanchezmaldonadojosemanuel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT calizrafael validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT lopeznevotmiguelangel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT cabreraserranoantoniojose validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT monizdiezana validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT canhaohelena validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT terhorstrob validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT quartuccioluca validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT sorensensigneb validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT glintborgbente validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT hetlandmeretel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT filipescuileana validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT perezpampineva validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT conesazamorapablo validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT swierkotjerzy validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT denbroederalfonsa validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT devitasalvatore validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT petersenevarabingbrix validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT liyang validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT ferrermiguela validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT escuderoalejandro validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT neteamihaig validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT coenenmariekejh validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT andersenvibeke validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT fonsecajoaoe validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT juradomanuel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT boguniakubikkatarzyna validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT collanteseduardo validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts AT sainzjuan validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts |